Cite

    Halvorsen, Y. et al. (2020). A 12‐week, randomized, double‐blind, placebo‐controlled, four‐arm dose‐finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes, obesity & metabolism. 22 (4), pp. 566-573. [Online].